You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Business

Biogen Idec seeks OK for hemophilia B treatment

Biogen Idec Inc. has applied to the Food and Drug Administration for approval to market a new treatment for hemophilia B, the Weston biotechnology company said Friday.

Hemophilia B is a rare inherited disease that keeps patients’ blood from clotting and can cause bleeding, joint damage, and life-threatening hemorrhages. Biogen Idec said it submitted its biologics license application to the FDA recently and expects a decision some time this year. It is the first product in a class of clotting therapies the company is developing.

Continue reading below

Biogen Idec said it is on track to submit a similar application for a drug to treat another form of the disease, hemophilia A, in the first quarter of this year.

The company, a global leader in multiple sclerosis drugs, said Thursday it was ending development of an experimental drug for Lou Gehrig’s disease after the drug proved ineffective in a late-phase clinical trial.

Robert Weisman can be reached at weisman@globe.com.
Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week